In LRC-CPPT, patients on cholestyramine, a bile acid sequestrant resin, had 20% lower LDL as compared to an 8% drop on placebo and, after seven years, had a 24% reduction in CV deaths versus placebo.

FORBES: Do We Really Need Head-To-Head Comparison Trials With Statins To Improve Cardiac Health?